Bulimia Nervosa (BN) is a serious and potentially life-threatening eating disorder mainly affecting females. BN is characterized by binge eating followed by purging, fasting, and other strategies to prevent weight gain. It has a lifetime prevalence of 1-2%, and patients are at a heightened risk of other psychiatric disorders including depression, anxiety and substance abuse. Fluoxetine is currently the only FDA approved medication to treat BN. However, the remission rate with fluoxetine, both alone and combination with psychotherapy, ranges only between 19-41%.
The compulsive bingeing characteristic of BN has features in common with other addictive disorders, providing the basis for using of opioid antagonists to mitigate their frequency.
Opiant has initiated a Phase 2 clinical trial to evaluate its novel, nasally-delivered opioid antagonist candidate, OPNT001, as a potential treatment for BN. The drug candidate has already demonstrated a rapid absorption profile, which together with a targeted dosing strategy, may address the unique needs of patients suffering from this serious disorder.